Changes of bone marrow microenvironment of myelodysplastic syndromes

doi:10.3760/cma.j.issn.1673422X.2016.09.019

Abstract

Abstract: Bone marrow microenvironment is a complex network consisting of hematopoietic stem/progenitor cells (HSPCs), nonhematopoietic cells, extracellular matrix and various cytokines. Its components interact to support normal hematopoiesis. Emerging evidence indicates that the dysfunction of mesenchymal stem cells, myeloidderived suppressor cells, cytokines and the epigenetic alterations of HSPCs in the bone marrow microenvironment could influence normal hematopoiesis. Abnormal hematopoiesis contributes to the occurrence of hematological malignancies, such as myelodysplastic syndromes (MDS). Animal models have confirmed that bone marrow microenvironment plays an important role in the original generation and maintenance of malignant diseases of hematopoietic system.

Key words: Myelodysplastic syndromes, Cytokines, Mesenchymal stem cells

SHEN Na, LI Qing, CHENG Fan-Jun. Changes of bone marrow microenvironment of myelodysplastic syndromes[J]. Journal of International Oncology, 2016, 43(8): 715-717.

References

［1］ Xiong H, Yang XY, Han J, et al. Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes［J］. Braz J Med Biol Res, 2015, 48(3)： 207213. DOI: 10.1590/1414431X20144051. ［2］ Bulycheva E, Rauner M, Medyouf H, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies［J］. Leukemia, 2015, 29(2)： 259268. DOI: 10.1038/leu.2014.325. ［3］ Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia［J］. Nature, 2010, 464(7290)： 852857. DOI: 10.1038/nature08851. ［4］ Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cellscurrent trends and future prospective［J］. Biosci Rep, 2015, 35(2)： e00191. DOI: 10.1042/BSR20150025. ［5］ Falconi G, Fabiani E, Fianchi L, et al. Impairment of PI3K/AKT and WNT/betacatenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes［J］. Exp Hematol, 2016, 44(1)： 7583. DOI: 10.1016/j.exphem.2015.10.005. ［6］ Blau O, Baldus CD, Hofmann WK, et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts［J］. Blood, 2011, 118(20)： 55835592. DOI: 10.1182/blood201103343467. ［7］ Geyh S, Oz S, Cadeddu RP, et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells［J］. Leukemia, 2013, 27(9)： 18411851. DOI: 10.1038/leu.2013.193. ［8］ Johnson RC, Kurzer JH, Greenberg PL, et al. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival［J］. Am J Clin Pathol, 2014, 142(6)： 795802. DOI: 10.1309/AJCP71OPHKOTLSUG. ［9］ Cogle CR, Saki N, Khodadi E, et al. Bone marrow niche in the myelodysplastic syndromes［J］. Leuk Res, 2015, 39(10)： 10201027. DOI: 10.1016/j.leukres.2015.06.017. ［10］Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloidderived suppressor cells［J］. J Clin Invest, 2013, 123(11)： 45954611. DOI: 10.1172/JCI67580. ［11］Gleason MK, Ross JA, Warlick ED, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets［J］. Blood, 2014, 123(19)： 30163026. DOI: 10.1182/blood201310533398. ［12］Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis［J］. Leuk Lymphoma, 2011, 52(11)： 20452049. DOI: 10.3109/10428194.2011.584002. ［13］Yang L, Qian Y, Eksioglu E, et al. The inflammatory microenvironment in MDS［J］. Cell Mol Life Sci, 2015, 72(10)： 19591966. DOI: 10.1007/s000180151846x. ［14］Kondo A, Yamashita T, Tamura H, et al. Interferongamma and tumor necrosis factoralpha induce an immunoinhibitory molecule, B7H1, via nuclear factorkappaB activation in blasts in myelodysplastic syndromes［J］. Blood, 2010, 116(7)： 11241131. DOI: 10.1182/blood200912255125. ［15］Kastrinaki MC, Pavlaki K, Batsali AK, et al. Mesenchymal stem cells in immunemediated bone marrow failure syndromes［J］. Clin Dev Immunol, 2013, 2013： 265608. DOI: 10.1155/2013/265608. ［16］Azizidoost S, Babashah S, Rahim F, et al. Bone marrow neoplastic niche in leukemia［J］. Hematology, 2014, 19(4)： 232238. DOI: 10.1179/1607845413Y.0000000111. ［17］Kim M, Hwang S, Park K, et al. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes［J］. PLoS One, 2015, 10(3)： e120602. DOI: 10.1371/journal.pone.0120602. ［18］Harada H, Harada Y. Recent advances in myelodysplastic syndromes: molecular pathogenesis and its implications for targeted therapies［J］. Cancer Sci, 2015, 106(4)： 329336. DOI: 10.1111/cas.12614. ［19］Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and bloodcancer risk inferred from blood DNA sequence［J］. N Engl J Med, 2014, 371(26)： 24772487. DOI: 10.1056/NEJMoa1409405. ［20］Prebet T, Gore SD, Esterni B, et al. Outcome of highrisk myelodysplastic syndrome after azacitidine treatment failure［J］. J Clin Oncol, 2011, 29(24)： 33223327. DOI: 10.1200/JCO

[1]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[2]	Liu Saisai, Yuan Dongya. Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment [J]. Journal of International Oncology, 2021, 48(4): 212-215.
[3]	Yang Aiwu, Lin Zhimin, Zhang Jiangling, Liang Renpei, Zheng Weibin. Effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy [J]. Journal of International Oncology, 2018, 45(3): 161-165.
[4]	Zhang-Jie, FANG Lin, ZHENG Jun-Nian- . Mesenchymal stem cellsbased cancer therapies [J]. Journal of International Oncology, 2015, 42(8): 612-615.
[5]	LI Rong, YANG Xiao-Yun, SHEN Li-Da. Malnutrition related factors in patients with gastric cancer [J]. Journal of International Oncology, 2015, 42(3): 221-223.
[6]	CHEN Hong-Shan, WANG Yu-Dong, LIU Wei. Epidemiology and pathogenesis research progress of cancer-related fatigue [J]. Journal of International Oncology, 2014, 41(3): 187-190.
[7]	HE Xue-Qun, HAN Ke-Qi. Key component of inflammatory microenvironment and tumor [J]. Journal of International Oncology, 2014, 41(3): 169-172.
[8]	LI Chuan, LI Yan, BAI Ying. Cytokines therapy in tumor treatment [J]. Journal of International Oncology, 2013, 40(8): 590-592.
[9]	CAI Kai, ZHANG Chuang, JIANG Tao. Immune responses and antitumor effects after radiofrequency ablation therapy in tumor patients [J]. Journal of International Oncology, 2013, 40(11): 826-829.
[10]	ZHOU Jun-Jun, LU Zhao-Tong. Mesenchymal stem cells in radiationinduced lung injury treatment [J]. Journal of International Oncology, 2012, 39(8): 706-708.
[11]	ZHAO Da-hang. Antitumor effect of inhibitor of growth 4 [J]. Journal of International Oncology, 2012, 39(6): 422-424.
[12]	LI Si-Yu, ZHAO Qing-Hua. Mesenchymal stem cells as carriers in cancer therapy [J]. Journal of International Oncology, 2012, 39(10): 748-751.